

Antithrombotic activity (%)
120
100
80
60
40
20
0
0.2
0.25
0.3
0.35
0.4
0.45
0.5
NOV1401 (mg/kg)
NOV1401
N=5-7/dose
Vehicle

FIG 1A



1.6x
aPTT clotting time (sec)
65
60
55
50
45
40
35
30
25
20
N=6
N=4
N=4
N=2
N=4
Vehicle
0.24
0.27
0.3
0.47
NOV1401 (mg/kg)

FIG 1B




FIG 1C



A
aPTT clotting time (sec)
Total plasma NOV1401 (nM)
2x aPTT
Study Day
NOV1401 (3 mg/kg)
NOV1401 (10 mg/kg)
NOV1401 (30 mg/kg)

FIG 2A



B
aPTT clotting time (sec)
Total plasma NOV1401 (nM)
2x aPTT
Study Day
NOV1401 (3 mg/kg)
NOV1401 (10 mg/kg)
NOV1401 (30 mg/kg)

FIG 2B



A
aPTT clotting time (sec)
Plasma Free FXI (nM)
Study Day
NOV1401
(3 mg/kg)
NOV1401
(10 mg/kg)
NOV1401
(30 mg/kg)

FIG 3A



B
aPTT clotting time (sec)
Plasma Free FXI (nM)
Study Day
NOV1401
(3 mg/kg)
NOV1401
(10 mg/kg)
NOV1401
(30 mg/kg)

FIG 3B



FXI CD
NOV1401 Fab
Active site
Light chain
Heavy chain

FIG 4A



NOV1401
Active site
fXI CD
Ile370
Apple domains

FIG 4B




FIG 5A




FIG 5B



Inhibition (%)
100
50
0
1E-4
1E-3
0.01
0.1
1
10
100
NOV1401 (nM)

FIG 6A



aPTT clotting time (seconds)
120
100
80
60
40
20
2 x aPTT
baseline
1
10
100
1000
NOV1401 (nM)

FIG 6B



600
500
400
300
200
100
0
Thrombin (nM)
residual thrombin
0.0001
0.001
0.01
0.1
1
NOV1401 (μM)

FIG 6C



aPTT in male cynomolgus monkeys
aPTT [sec]
65
60
55
50
45
40
35
30
25
20
15
-5
0
10
20
30
40
50
60
70
80
pre-dose
day 1 of treatment
Study Day
0 mg/kg SC + IV
10 mg/kg SC
100 mg/kg SC
50 mg/kg IV
aPTT in female cynomolgus monkeys
aPTT [sec]
65
60
55
50
45
40
35
30
25
20
15
-5
0
10
20
30
40
50
60
70
80
pre-dose
day 1 of treatment
Study Day
0 mg/kg SC + IV
10 mg/kg SC
100 mg/kg SC
50 mg/kg IV

FIG 7A



FXI activity in male cynomolgus monkeys
FXI activity [%]
200
180
160
140
120
100
80
60
40
20
0
-5
0
10
20
30
40
50
60
70
80
pre-dose
day 1 of treatment
Study Day
0 mg/kg SC + IV
10 mg/kg SC
100 mg/kg SC
50 mg/kg IV
FXI activity in female cynomolgus monkeys
FXI activity [%]
200
180
160
140
120
100
80
60
40
20
0
-5
0
10
20
30
40
50
60
70
80
pre-dose
day 1 of treatment
Study Day
0 mg/kg SC + IV
10 mg/kg SC
100 mg/kg SC
50 mg/kg IV

FIG 7B